inactivated COVID-19 vaccine (Omicron variant)
/ Sinovac
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 31, 2024
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
(clinicaltrials.gov)
- P3 | N=1750 | Completed | Sponsor: Sinovac Research and Development Co., Ltd. | Recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease
January 12, 2023
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
(clinicaltrials.gov)
- P3 | N=1750 | Recruiting | Sponsor: Sinovac Research and Development Co., Ltd. | Trial primary completion date: Nov 2022 ➔ Apr 2023
Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
June 21, 2022
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
(clinicaltrials.gov)
- P3 | N=1750 | Recruiting | Sponsor: Sinovac Research and Development Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease
1 to 3
Of
3
Go to page
1